|

Gemcitabine-nab-paclitaxel Clinical Trials

6 actively recruiting trials across 4 locations

Also known as: (G-nP), abraxane

Pipeline

Phase 1: 2Phase 2: 1Phase 1/2: 3

Top Sponsors

  • Zhejiang University1
  • Verastem, Inc.1
  • Tango Therapeutics, Inc.1
  • ProDa BioTech, LLC1
  • Phanes Therapeutics1

Indications

  • Cancer6
  • Pancreatic Ductal Adenocarcinoma3
  • Lung Cancer3
  • Non Small Cell Lung Cancer2
  • G12D Mutated KRAS1

Other2 trials

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
Phase 2
Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
Phase 1

Birmingham, Alabama1 trial

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

O'Neal Comprehensive Cancer Center, University of Alabama

Phase 1

Scottsdale, Arizona1 trial

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Mayo Clinic Scottsdale

Phase 1/2

Los Angeles, California1 trial

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Cedars-Sinai Medical Center

Phase 1/2

Huntersville, North Carolina1 trial

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Carolina BioOncology Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.